At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver on alongside their local medicines optimisation priorities. Progress against chosen opportunities will be reviewed using available data.

The RDTC has developed a Northern regions dashboard to highlight the current position of the ICBs across the North of England in relation to these 16 priorities. It will incorporate the metrics that are being developed nationally, but also include metrics which are designed to support medicines optimisation opportunities across the North.

Metrics within this dashboard continue to be developed and updates will be communicated out to stakeholders as they happen. We do not at this time intend to include sub ICB level data.

Stakeholders can find the dashboard at this link.